Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C Meeting Abstract
| Authors: | Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; Rosenberg, J. E.; Matsubara, N.; Sokolowski, K. M.; Ichimaru, M.; Chan, S.; Franco, S.; Powles, T. B. |
| Abstract Title: | Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1138 |
| End Page: | S1139 |
| Language: | English |
| ACCESSION: | WOS:001326612902582 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2024.08.2052 |
| Notes: | Meeting Abstract: 1967MO -- Source: Wos |
